Gemcitabine resistance in breast cancer cells regulated by PIi3K/AaKT-mediated cellular proliferation exerts negative feedback via the MEK/MAaPK and mTORr pathways

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1033-1042

  Yang, Xiao Li ^a   Lin, Feng Juan ^a   Gguo, Ya Jie ^a   Shao, Zhi Min ^a   Ou, Zhou Luo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Chemoresistance; Gemcitabine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE PHOSPHATE; CYCLIN D1; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; S6 KINASE; SYNAPTOPHYSIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MDA MB 231 CELL LINE; MICROSCOPY; NEGATIVE FEEDBACK; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; WESTERN BLOTTING;

EID: 84902458910     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S63145     Document Type: Article

References (35)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64(1): 52-62.
2. Zhang ML, Huang ZZ, Zheng Y. [Estimates and prediction on incidence, mortality and prevalence of breast cancer in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012; 33(10): 1049-1051. Chinese.
3. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res Treat. 2005; 90(1): 25-31.
4. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002; 29(6 Suppl 20): 9-16.
5. Kohail H, Shehata S, Mansour O, et al. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. Hematol Oncol Stem Cell Ther. 2012; 5(1): 42-48.
6. Erten C, Demir L, Somali I, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev. 2013; 14(6): 3711-3717.
7. Franchina T, Adamo B, Ricciardi GR, et al. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther. 2012; 13(7): 472-476.
8. Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012; 1(1): 29.
9. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16(12): 1472-1487.
10. Wang L, Liu Q, Li F, et al. Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. Oncol Rep. 2013; 30(4): 1631-1638.
11. Kumar D, Shankar S, Srivastava RK. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2014; 343(2): 179-189.
12. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004; 23(18): 3151-3171.
13. Pola C, Formenti SC, Schneider RJ. Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res. 2013; 73(14): 4571-4578.
14. Dragowska WH, Verreault M, Yapp DT, et al. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. 2007; 106(3): 319-331.
15. Jung CH, Kim H, Ahn J, et al. Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition. Evid Based Complement Alternat Med. 2013; 2013: 385219.
16. Cho YH, Han KM, Kim D, et al. Autophagy regulates homeostasis of pluripotency-associated proteins in hESCs. Stem Cells. 2014; 32(2): 424-435.
17. Lorin S. [Leucine sensing in the regulation of autophagy: glutamate dehydrogenase is on the way]. Med Sci (Paris). 2013; 29(10): 839-842. French.
18. Wei PF, Zhang L, Nethi SK, et al. Accelerating the clearance of mutant huntingtin protein aggregates through autophagy induction by europium hydroxide nanorods. Biomaterials. 2014; 35(3): 899-907.
19. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010; 6(2): 239-247.
20. Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013; 39(8): 935-946.
21. Woo CC, Hsu A, Kumar AP, Sethi G, Tan KH. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One. 2013; 8(10): e75356.
22. Gil-Araujo B, Toledo Lobo MV, Gutiérrez-Salmerón M, et al. Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol Oncol. 2014; 8(1): 27-38.
23. Ko JC, Chiu HC, Wo TY, et al. Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells. Lung Cancer. 2013; 82(3): 397-406.
24. Zhang B, Wang X, Cai F, Chen W, Loesch U, Zhong XY. Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation. Oncol Rep. 2013; 29(4): 1371-1378.
25. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004; 64(11): 3761-3766.
26. Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer. 2013; 14(4): 322-332.
27. Hoang B, Benavides A, Shi Y, et al. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem. 2012; 287(26): 21796-21805.
28. McCubrey JA, Steelman LS, Chappell WH, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012; 3(10): 1068-1111.
29. Xu ZH, Hang JB, Hu JA, Gao BL. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. Int J Clin Exp Pathol. 2013; 6(8): 1493-1504.
30. Zheng C, Jiao X, Jiang Y, Sun S. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J Int Med Res. 2013; 41(2): 300-306.
31. Mei K, Wang L, Tian L, Yu J, Zhang Z, Wei Y. Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model. J Exp Clin Cancer Res. 2008; 27: 63.
32. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010; 103(11): 1671-1679.
33. Liang K, Lu Y, Li X, et al. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006; 70(3): 1045-1052.
34. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007; 102(2): 157-172.
35. Kagawa S, Takano S, Yoshitomi H, et al. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res. 2012; 178(2): 758-767.